[How I treat vasovagal syncope in children]. [PDF]
Zou RM, Wang C.
europepmc +1 more source
[Research progress of molecular imprinting technology in the field of disease diagnosis and therapy]. [PDF]
Zhu R, Cai GP, Zheng HJ, Jia Q.
europepmc +1 more source
[Resveratrol protects barrier function of mouse brain microvascular endothelial cell monolayers with oxygen/glucose deprivation and PM<sub>2.5</sub> exposure by maintaining mitochondrial dynamics balance]. [PDF]
Qin M +9 more
europepmc +1 more source
[cGAS-STING agonist cGAMP enhances natural killer cell-mediated cytotoxicity against gastric cancer cells]. [PDF]
Wang Q +6 more
europepmc +1 more source
[Research progress on biologics and therapeutic drug monitoring in pediatric inflammatory bowel disease]. [PDF]
Pan TT, Yang HL, Zhou SH, Sun H.
europepmc +1 more source
[<i>Xuebijing</i> Injection in synergy with linezolid alleviates inflammatory injury in mice with MRSA pneumonia by inhibiting the Hla-NLRP3 pathway]. [PDF]
Yin M, Li R, Yang K, Jiao W, Liu X.
europepmc +1 more source
[Fabrication of high-degradation-efficiency molecularly imprinted photocatalysts and its selective degradation performance]. [PDF]
Zhang JJ +4 more
europepmc +1 more source
【目的】 评估血管紧张素Ⅱ受体阻断剂(ARB)在老年糖尿病患者中应用的有效性和安全性?【方法】 56例大于65岁老年2型糖尿病患者,随机分为治疗组和对照组,治疗组予氯沙坦口服,剂量50 ~ 100 mg/d,对照组不给上述治疗?饮食?运动?降糖?降脂等治疗方法两组相同?观察患者预先设定的研究终点事件的发生率(研究终点包括血清肌酐浓度的加倍,发生终末期肾脏疾病以及死亡)和不良事件发生情况?【结果】 经过1年的观察,氯沙坦治疗组能有效地降低试验的主要研究终点发生的危险性?不良事件(如血肌肝的升高和高钾血症 ...
doaj
[Clinical research advances for small-molecule nucleic acid drugs in the treatment of chronic hepatitis B]. [PDF]
Wang WX +4 more
europepmc +1 more source
[Cajanonic acid A derivative XJ-60 improves liver fibrosis in mice with non-alcoholic fatty liver disease by inhibiting the SP1/TGF-β/Smad3 signaling axis]. [PDF]
Geng Z +8 more
europepmc +1 more source

